Parker, J.L. et al. 2011. Clinical Trial Risk in Non-Hodgkin’s Lymphoma: Endpoint and Target Selection. Journal of Pharmacy & Pharmaceutical Sciences. 14, 2 (Jun. 2011), 227–235. DOI:https://doi.org/10.18433/J39P45.